Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:10637495rdf:typepubmed:Citationlld:pubmed
pubmed-article:10637495lifeskim:mentionsumls-concept:C0086418lld:lifeskim
pubmed-article:10637495lifeskim:mentionsumls-concept:C0026764lld:lifeskim
pubmed-article:10637495lifeskim:mentionsumls-concept:C0007620lld:lifeskim
pubmed-article:10637495lifeskim:mentionsumls-concept:C0003250lld:lifeskim
pubmed-article:10637495lifeskim:mentionsumls-concept:C0243192lld:lifeskim
pubmed-article:10637495lifeskim:mentionsumls-concept:C0018284lld:lifeskim
pubmed-article:10637495lifeskim:mentionsumls-concept:C0040661lld:lifeskim
pubmed-article:10637495lifeskim:mentionsumls-concept:C1705162lld:lifeskim
pubmed-article:10637495pubmed:issue1lld:pubmed
pubmed-article:10637495pubmed:dateCreated2000-2-2lld:pubmed
pubmed-article:10637495pubmed:abstractTextWe have previously reported obtaining two monoclonal antibodies (mAb) against the human gp130 interleukin-6 (IL-6) transducer which made possible the dimerization of gp130 and the activation of several IL-6-driven functions when used together. We report here that these mAb induce gp130-mediated signaling in human myeloma cells and support the survival and the long-term growth of five IL-6-dependent human myeloma cell lines. Their agonist activity is not affected by neutralizing antibodies to IL-6 or IL-6R. These mAb induce a transient proliferation of primary myeloma cells from most patients with multiple myeloma. Again, IL-6 inhibitors do not affect this agonist activity. By using highly purified primary myeloma cells, we found that these anti-gp130 mAb supported the long-term survival of primary myeloma cells from five patients with primary plasma cell leukemia but failed to induce their long-term growth. For patients with fulminant disease and secondary extramedullary proliferation, the antibodies supported a long-term survival and growth, and anti-gp130 mAb-dependent cell lines were obtained. For patients with medullary involvement only, a co-stimulatory signal is necessary, together with gp130 activation, to trigger cell survival and cycling. Leukemia (2000) 14, 188-197.lld:pubmed
pubmed-article:10637495pubmed:languageenglld:pubmed
pubmed-article:10637495pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10637495pubmed:citationSubsetIMlld:pubmed
pubmed-article:10637495pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10637495pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10637495pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10637495pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10637495pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10637495pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10637495pubmed:statusMEDLINElld:pubmed
pubmed-article:10637495pubmed:monthJanlld:pubmed
pubmed-article:10637495pubmed:issn0887-6924lld:pubmed
pubmed-article:10637495pubmed:authorpubmed-author:WijdenesJJlld:pubmed
pubmed-article:10637495pubmed:authorpubmed-author:KleinBBlld:pubmed
pubmed-article:10637495pubmed:authorpubmed-author:ZhangX GXGlld:pubmed
pubmed-article:10637495pubmed:authorpubmed-author:De VosJJlld:pubmed
pubmed-article:10637495pubmed:authorpubmed-author:RossiJ FJFlld:pubmed
pubmed-article:10637495pubmed:authorpubmed-author:JourdanMMlld:pubmed
pubmed-article:10637495pubmed:authorpubmed-author:GuZ JZJlld:pubmed
pubmed-article:10637495pubmed:authorpubmed-author:RebouissouCClld:pubmed
pubmed-article:10637495pubmed:issnTypePrintlld:pubmed
pubmed-article:10637495pubmed:volume14lld:pubmed
pubmed-article:10637495pubmed:ownerNLMlld:pubmed
pubmed-article:10637495pubmed:authorsCompleteYlld:pubmed
pubmed-article:10637495pubmed:pagination188-97lld:pubmed
pubmed-article:10637495pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:10637495pubmed:meshHeadingpubmed-meshheading:10637495...lld:pubmed
pubmed-article:10637495pubmed:meshHeadingpubmed-meshheading:10637495...lld:pubmed
pubmed-article:10637495pubmed:meshHeadingpubmed-meshheading:10637495...lld:pubmed
pubmed-article:10637495pubmed:meshHeadingpubmed-meshheading:10637495...lld:pubmed
pubmed-article:10637495pubmed:meshHeadingpubmed-meshheading:10637495...lld:pubmed
pubmed-article:10637495pubmed:meshHeadingpubmed-meshheading:10637495...lld:pubmed
pubmed-article:10637495pubmed:meshHeadingpubmed-meshheading:10637495...lld:pubmed
pubmed-article:10637495pubmed:meshHeadingpubmed-meshheading:10637495...lld:pubmed
pubmed-article:10637495pubmed:meshHeadingpubmed-meshheading:10637495...lld:pubmed
pubmed-article:10637495pubmed:meshHeadingpubmed-meshheading:10637495...lld:pubmed
pubmed-article:10637495pubmed:meshHeadingpubmed-meshheading:10637495...lld:pubmed
pubmed-article:10637495pubmed:meshHeadingpubmed-meshheading:10637495...lld:pubmed
pubmed-article:10637495pubmed:meshHeadingpubmed-meshheading:10637495...lld:pubmed
pubmed-article:10637495pubmed:year2000lld:pubmed
pubmed-article:10637495pubmed:articleTitleAgonist anti-gp130 transducer monoclonal antibodies are human myeloma cell survival and growth factors.lld:pubmed
pubmed-article:10637495pubmed:affiliationINSERM U475, Immunopathologie des Maladies Tumorales et Autoimmmunes, Montpellier, France.lld:pubmed
pubmed-article:10637495pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:10637495pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:10637495lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:10637495lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:10637495lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:10637495lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:10637495lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:10637495lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:10637495lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:10637495lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:10637495lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:10637495lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:10637495lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:10637495lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:10637495lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:10637495lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:10637495lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:10637495lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:10637495lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:10637495lld:pubmed